Annual Cash & Cash Equivalents
$966.43 M
+$153.74 M+18.92%
December 31, 2024
Summary
- As of February 20, 2025, ALNY annual cash & cash equivalents is $966.43 million, with the most recent change of +$153.74 million (+18.92%) on December 31, 2024.
- During the last 3 years, ALNY annual cash & cash equivalents has risen by +$146.45 million (+17.86%).
- ALNY annual cash & cash equivalents is now at all-time high.
Performance
ALNY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$966.43 M
-$133.49 M-12.14%
December 31, 2024
Summary
- As of February 20, 2025, ALNY quarterly cash and cash equivalents is $966.43 million, with the most recent change of -$133.49 million (-12.14%) on December 31, 2024.
- Over the past year, ALNY quarterly cash and cash equivalents has increased by +$153.74 million (+18.92%).
- ALNY quarterly cash and cash equivalents is now -14.95% below its all-time high of $1.14 billion, reached on June 30, 2019.
Performance
ALNY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ALNY Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.9% | +18.9% |
| 3 y3 years | +17.9% | +18.9% |
| 5 y5 years | +76.6% | +18.9% |
ALNY Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +18.9% | -12.1% | +81.0% |
| 5 y | 5-year | at high | +94.6% | -12.1% | +154.6% |
| alltime | all time | at high | +6144.3% | -14.9% | >+9999.0% |
Alnylam Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $966.43 M(+18.9%) | $966.43 M(-12.1%) |
| Sep 2024 | - | $1.10 B(+13.6%) |
| Jun 2024 | - | $968.49 M(+42.0%) |
| Mar 2024 | - | $681.88 M(-16.1%) |
| Dec 2023 | $812.69 M(-6.2%) | $812.69 M(-21.3%) |
| Sep 2023 | - | $1.03 B(+57.0%) |
| Jun 2023 | - | $657.80 M(-2.1%) |
| Mar 2023 | - | $672.25 M(-22.4%) |
| Dec 2022 | $866.39 M(+5.7%) | $866.39 M(-19.3%) |
| Sep 2022 | - | $1.07 B(+86.5%) |
| Jun 2022 | - | $575.56 M(+7.8%) |
| Mar 2022 | - | $534.08 M(-34.9%) |
| Dec 2021 | $819.98 M(+65.1%) | $819.98 M(-25.0%) |
| Sep 2021 | - | $1.09 B(+46.7%) |
| Jun 2021 | - | $745.77 M(+96.5%) |
| Mar 2021 | - | $379.54 M(-23.6%) |
| Dec 2020 | $496.58 M(-9.2%) | $496.58 M(-0.0%) |
| Sep 2020 | - | $496.70 M(-14.5%) |
| Jun 2020 | - | $580.83 M(+24.2%) |
| Mar 2020 | - | $467.78 M(-14.5%) |
| Dec 2019 | $547.18 M(+30.2%) | $547.18 M(-40.7%) |
| Sep 2019 | - | $923.30 M(-18.7%) |
| Jun 2019 | - | $1.14 B(+56.7%) |
| Mar 2019 | - | $724.96 M(+72.5%) |
| Dec 2018 | $420.15 M(-34.9%) | $420.15 M(+32.7%) |
| Sep 2018 | - | $316.61 M(-12.4%) |
| Jun 2018 | - | $361.46 M(-8.8%) |
| Mar 2018 | - | $396.15 M(-38.6%) |
| Dec 2017 | $645.36 M(+233.3%) | $645.36 M(+219.4%) |
| Sep 2017 | - | $202.04 M(-50.6%) |
| Jun 2017 | - | $408.67 M(+138.9%) |
| Mar 2017 | - | $171.08 M(-11.6%) |
| Dec 2016 | $193.62 M(+7.0%) | $193.62 M(+14.9%) |
| Sep 2016 | - | $168.48 M(-37.8%) |
| Jun 2016 | - | $271.08 M(+17.2%) |
| Mar 2016 | - | $231.28 M(+27.9%) |
| Dec 2015 | $180.90 M(+140.6%) | $180.90 M(+21.2%) |
| Sep 2015 | - | $149.22 M(-1.4%) |
| Jun 2015 | - | $151.26 M(-50.7%) |
| Mar 2015 | - | $306.58 M(+307.8%) |
| Dec 2014 | $75.18 M | $75.18 M(-9.1%) |
| Sep 2014 | - | $82.72 M(+2.5%) |
| Jun 2014 | - | $80.73 M(-77.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $350.59 M(+559.4%) |
| Dec 2013 | $53.17 M(+3.4%) | $53.17 M(+349.1%) |
| Sep 2013 | - | $11.84 M(-52.6%) |
| Jun 2013 | - | $24.98 M(-74.5%) |
| Mar 2013 | - | $97.80 M(+90.3%) |
| Dec 2012 | $51.41 M(-26.8%) | $51.41 M(-32.2%) |
| Sep 2012 | - | $75.84 M(+57.1%) |
| Jun 2012 | - | $48.27 M(-21.8%) |
| Mar 2012 | - | $61.74 M(-12.1%) |
| Dec 2011 | $70.23 M(-5.9%) | $70.23 M(-5.5%) |
| Sep 2011 | - | $74.34 M(+10.8%) |
| Jun 2011 | - | $67.11 M(-25.9%) |
| Mar 2011 | - | $90.59 M(+21.4%) |
| Dec 2010 | $74.60 M(-45.7%) | $74.60 M(+59.1%) |
| Sep 2010 | - | $46.88 M(-29.2%) |
| Jun 2010 | - | $66.18 M(-42.4%) |
| Mar 2010 | - | $114.95 M(-16.4%) |
| Dec 2009 | $137.47 M(-28.3%) | $137.47 M(+40.1%) |
| Sep 2009 | - | $98.09 M(-33.7%) |
| Jun 2009 | - | $147.87 M(-34.9%) |
| Mar 2009 | - | $227.27 M(+18.5%) |
| Dec 2008 | $191.79 M(+82.4%) | $191.79 M(-2.5%) |
| Sep 2008 | - | $196.74 M(-20.5%) |
| Jun 2008 | - | $247.54 M(+26.1%) |
| Mar 2008 | - | $196.28 M(+86.7%) |
| Dec 2007 | $105.16 M(-17.8%) | $105.16 M(-47.6%) |
| Sep 2007 | - | $200.55 M(+137.4%) |
| Jun 2007 | - | $84.46 M(+26.7%) |
| Mar 2007 | - | $66.66 M(-47.9%) |
| Dec 2006 | $127.95 M(+712.1%) | $127.95 M(+260.3%) |
| Sep 2006 | - | $35.52 M(-0.4%) |
| Jun 2006 | - | $35.65 M(-37.2%) |
| Mar 2006 | - | $56.80 M(+260.5%) |
| Dec 2005 | $15.76 M(-22.3%) | $15.76 M(+119.5%) |
| Sep 2005 | - | $7.18 M(-21.7%) |
| Jun 2005 | - | $9.16 M(-25.0%) |
| Mar 2005 | - | $12.21 M(-39.7%) |
| Dec 2004 | $20.27 M(-12.6%) | $20.27 M(+39.4%) |
| Sep 2004 | - | $14.54 M(-54.4%) |
| Jun 2004 | - | $31.89 M(+47.6%) |
| Mar 2004 | - | $21.61 M(-6.8%) |
| Dec 2003 | $23.19 M(+49.9%) | $23.19 M |
| Dec 2002 | $15.48 M | - |
FAQ
- What is Alnylam Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Alnylam Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Alnylam Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of ALNY is $966.43 M
What is the all time high annual cash & cash equivalents for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual cash & cash equivalents is $966.43 M
What is Alnylam Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, ALNY annual cash & cash equivalents has changed by +$153.74 M (+18.92%)
What is Alnylam Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ALNY is $966.43 M
What is the all time high quarterly cash and cash equivalents for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly cash and cash equivalents is $1.14 B
What is Alnylam Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, ALNY quarterly cash and cash equivalents has changed by +$153.74 M (+18.92%)